Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Market makers move to downside ETFs


Bookmark and Share

 "ETFs are now being used as tactical and strategic tools, both by individual investors, and more influentially, by professional investors," notes Peter Way, who analyzes the activities of million dollar market makers.

In his Block Trader ETF Monitor he notes, "In just two recent weeks there have been $1.5 billion of new bets against the stock market’s rising." Here, he looks at their downside bets.

"The total now bet against the market rising is over $10 billion, in the column to the left. And most of the big bets have been in levered short instruments, where the payoff for being bearish is about doubled.

Advertisement
Banner

"A quick explanation of these ETFs may be useful. These are instruments that investors can buy long, like ordinary stock investments, but they have been so constructed from the outset that when prices of the holdings of the fund go down, the price of the fund goes up.

"No worry about unlimited losses from being short something that grows to the sky. They are a simple feat of financial engineering that is completely legal and well thought out.

"Their levered cousins take the financial engineering a step further. In effect they use the margin rules to accomplish a near-2-for-1 price impact, but all within the initial structure of the ETF.

"Now there is no further worry about margin calls from your broker. All the adjustments are taken care of automatically at the ETF headquarters and are simply reflected in the market value of the instrument.

"We’re not negative on this kind of strategy, as long as it is well-founded and clearly understood. Market history shows that corrections usually are much briefer than bull periods, so it is important to stay on your toes and pay attention when in these instruments.

"INdeed, our analysis of activities by million dollar market makers suggest that Proshares Ultra Short Nasdaq 100 Index ETF (ASE: QID) may be one of the best bets at present. If you are looking for thrills and spills, here you are, but stay alert.

"In addition, some investors think China investing may have gotten overdone. In response, the ETF community brought forth the ProShares UltraShort FTSE/Xinhua 25 (ASE: FXP), a levered short version of the FTSE/Xinhua 25 Index. In this case, $769 million of investment has been attracted by the FXP in 3 months since November.

"Among sectors, there are three levered short ETFs that look appealing. One is ProShares UltraShort Oil & Gas ETF (ASE: DUG), another is Proshares UltraShort Real Estate ETF (ASE: SRS), and the third is ProShares UltraShort Financials (ASE: SKF).

"Apparently all three have a cadre of convinced believers that the stocks in their holdings are headed down, and the market-makers seem to agree."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary